Payment overview · 2025
General Payments
$83.51
4 reported records · 3 companies
Healthcare provider profile · identity verified
Jon Gregory Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COUNCIL BLUFFS, IA · NPI 1437209434
Verified facts
What the public records show
CMS Open Payments records show Jon Gregory Thomas, M.D. received $83.51 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.60 | 41.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.87 | 33.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.04 | 25.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.51 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| OZURDEX Normalized: ozurdex |
Drug | ABBVIE INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 935 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 693 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 621 | 140 |
| Omeprazole | Omeprazole | 556 | 148 |
| Gabapentin | Gabapentin | 461 | 93 |
| Potassium Chloride | Potassium Chloride | 363 | 91 |
| Metformin Hcl | Metformin Hcl | 346 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 345 | 84 |
| Eliquis | Apixaban | 336 | 56 |
| Furosemide | Furosemide | 329 | 71 |
| Alprazolam | Alprazolam | 328 | 64 |
| Tramadol Hcl | Tramadol Hcl | 324 | 63 |
| Lisinopril | Lisinopril | 313 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 59 |
| Simvastatin | Simvastatin | 233 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 54 |
| Trazodone Hcl | Trazodone Hcl | 196 | 47 |
| Losartan Potassium | Losartan Potassium | 181 | 58 |
| Allopurinol | Allopurinol | 176 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 43 |
| Prednisone | Prednisone | 166 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 161 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 159 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 157 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 40 |
| Lorazepam | Lorazepam | 156 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 24 |
| Pregabalin | Pregabalin | 151 | 32 |
| Sertraline Hcl | Sertraline Hcl | 148 | 34 |
| Warfarin Sodium | Warfarin Sodium | 147 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 41 |
| Carvedilol | Carvedilol | 140 | 36 |
| Meloxicam | Meloxicam | 135 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 33 |
| Glimepiride | Glimepiride | 119 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 25 |
| Mirtazapine | Mirtazapine | 114 | 31 |
| Mounjaro | Tirzepatide | 111 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 32 |
| Xarelto | Rivaroxaban | 98 | 22 |
| Trulicity | Dulaglutide | 97 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 23 |
| Valsartan | Valsartan | 95 | 22 |
| Spironolactone | Spironolactone | 89 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 88 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | 12 |
| Famotidine | Famotidine | 82 | 21 |
| Fenofibrate | Fenofibrate | 79 | 21 |
| Montelukast Sodium | Montelukast Sodium | 78 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 18 |
| Metformin Hcl Er | Metformin Hcl | 72 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 50 |
| Donepezil Hcl | Donepezil Hcl | 69 | 15 |
| Topiramate | Topiramate | 67 | 14 |
| Celecoxib | Celecoxib | 66 | 21 |
| Finasteride | Finasteride | 65 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 22 |
| Benazepril Hcl | Benazepril Hcl | 61 | 19 |
| Buspirone Hcl | Buspirone Hcl | 60 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 14 |
| Ozempic | Semaglutide | 59 | 11 |
| Aripiprazole | Aripiprazole | 58 | 11 |
| Bupropion Xl | Bupropion Hcl | 58 | 16 |
| Telmisartan | Telmisartan | 58 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 41 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 12 |
| Baclofen | Baclofen | 54 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Alendronate Sodium | Alendronate Sodium | 53 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Torsemide | Torsemide | 53 | 18 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Linzess | Linaclotide | 51 | suppressed |
| Naproxen | Naproxen | 51 | 23 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 48 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Ondansetron Odt | Ondansetron | 48 | 17 |
| Colestipol Hcl | Colestipol Hcl | 47 | 19 |
| Estradiol | Estradiol | 47 | 15 |
| Levetiracetam | Levetiracetam | 47 | 14 |
| Clonazepam | Clonazepam | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 34 |
| Amoxicillin | Amoxicillin | 45 | 32 |
| Atenolol | Atenolol | 44 | 12 |
| Diazepam | Diazepam | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Mupirocin | Mupirocin | 44 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 31 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Premarin | Estrogens, Conjugated | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 24 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lubiprostone | Lubiprostone | 30 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Bumetanide | Bumetanide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | 11 |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.51 · 4 records | ABBVIE INC. | CAPLYTA, DALVANCE, FANAPT, HETLIOZ, OZURDEX, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error